Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation

We have cloned a human Hevin cDNA from omental adipose tissue of different patients by reverse transcription polymerase chain reaction and shown a sequence variation due to a possible polymorphism at amino acid position 161 (E/G). Hevin protein expressed in vitro showed molecular weights of approximately 75 kDa and 150 kDa, suggesting that Hevin may form a homodimer in vitro. Using Northern blots and a human expressed sequence tAg database analysis, Hevin was shown to be widely expressed in human normal or non-neoplastic diseased tissues with various levels. In contrast to this, its expression was strongly down-regulated in most neoplastic cells or tissues tested. However, neither the mechanism nor the physiological meaning of this down-regulation is known. As an initial step towards investigating the functional role of Hevin in cell growth and differentiation, we transiently or stably expressed this gene in cancer cells (HeLa 3S) that are devoid of endogenous Hevin and measured DNA synthesis (cell proliferation) by 5-bromo-2′-deoxyuridine incorporation. Hevin was shown to be a negative regulator of cell proliferation. Furthermore, we have shown that Hevin can inhibit progression of cells from G1 to S phase or prolong G1 phase. This is the first report which describes the function of Hevin in cell growth and proliferation. Through database analysis, Hevin was found to be located on chromosome 4 which contains loss of heterozygosity of many tumour suppressor genes. Taken together, these results suggest that Hevin may be a candidate for a tumour suppressor gene and a potential target for cancer diagnosis/therapy. © 2000 Cancer Research Campaign

[1]  N. Keiding,et al.  Long-term storage of samples for flow cytometric DNA analysis. , 1983, Cytometry.

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  E. Sage,et al.  The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Poellinger,et al.  Functional interference between the ubiquitous and constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct protein-protein interaction involving the homeo subdomain of OTF-1 , 1992, Molecular and cellular biology.

[6]  C. Downes,et al.  Cooperation of Src Homology Domains in the Regulated Binding of Phosphatidylinositol 3-Kinase , 1995, The Journal of Biological Chemistry.

[7]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[8]  T. Springer,et al.  Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. , 1995, Immunity.

[9]  R. Weinberg.  The Molecular Basis of Oncogenes and Tumor Suppressor Genes , 1995, Annals of the New York Academy of Sciences.

[10]  E. Orias,et al.  Genetic map of randomly amplified DNA polymorphisms closely linked to the mating type locus of Tetrahymena thermophila. , 1995, Genetics.

[11]  T. Springer,et al.  Modulation of Endothelial Cell Adhesion by Hevin, an Acidic Protein Associated with High Endothelial Venules (*) , 1996, The Journal of Biological Chemistry.

[12]  R. Weinberg,et al.  How cancer arises. , 1996, Scientific American.

[13]  R. Schimke,et al.  Tetracycline-controlled gene expression system achieves high-level and quantitative control of gene expression. , 1996, Analytical biochemistry.

[14]  R. Berkowitz,et al.  SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.

[15]  D. Faxon,et al.  Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. , 1996, The Journal of clinical investigation.

[16]  P. Chambon,et al.  Isolation of retinoic acid-repressed genes from P19 embryonal carcinoma cells. , 1996, Gene.

[17]  S. Ritland,et al.  Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. , 1997, Cancer research.

[18]  K. Ogawa,et al.  Loss of heterozygosity at loci on chromosome 4, a common genetic event during the spontaneous immortalization of mouse embryonic fibroblasts , 1997, Molecular carcinogenesis.

[19]  E. Lander,et al.  Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Papas,et al.  Isolation of a cDNA clone from colon carcinoma. , 1997, Anticancer research.

[21]  G. Fulci,et al.  p53 and Brain Tumors: From Gene Mutations to Gene Therapy , 1998, Brain pathology.

[22]  D. Gallagher,et al.  Candidate gene analysis of GH1 for effects on growth and carcass composition of cattle. , 1998, Animal genetics.

[23]  S. Hirohashi.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. , 1998, The American journal of pathology.

[24]  O. Boss,et al.  Quantification of the full length leptin receptor (OB-Rb) in human brown and white adipose tissue. , 1997, Life sciences.

[25]  Chen Qr,et al.  Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. , 1998 .

[26]  P. Schraml,et al.  Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. , 1998, Cancer research.

[27]  M. Herranz,et al.  A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4 , 1998, Oncogene.

[28]  D. Louis,et al.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.

[29]  L. Hood,et al.  Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. , 1998, Cancer research.

[30]  H. Tsuda,et al.  p16 gene overexpression in mouse bladder carcinomas. , 1998, Cancer letters.

[31]  T. Jacks,et al.  Regulation of the Neurofibromatosis Type 2 Tumor Suppressor Protein, Merlin, by Adhesion and Growth Arrest Stimuli* , 1998, The Journal of Biological Chemistry.